Ironwood Pharmaceuticals (IRWD) Stock Price, News & Analysis

Company Overview

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Key Stats

• Today's Range: $4.37 to $4.56
• 50-Day Range: $3.93 to $5.11
• 52-Week Range: $3.79 to $15.70
• Volume: 899,949 shs
• Average Volume: 3.08 million shs
• Market Capitalization: $694.99 million
• P/E Ratio: 111.00
• Dividend Yield: N/A
• Price Target: $12.17
• Consensus Rating: Moderate Buy

Ironwood Pharmaceuticals Stock Analysis - MarketRank™

Ironwood Pharmaceuticals scored higher than 97% of companies evaluated by MarketBeat, and ranked 60th out of 1,012 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Ironwood Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Ironwood Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 41.67%

Earnings Growth

Earnings for Ironwood Pharmaceuticals are expected to grow by 41.67% in the coming year, from $0.24 to $0.34 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ironwood Pharmaceuticals is 111.00, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.47.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ironwood Pharmaceuticals is 111.00, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 139.27.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.58% of the float of Ironwood Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Ironwood Pharmaceuticals has recently increased by 1.55%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ironwood Pharmaceuticals does not currently pay a dividend.

Dividend Growth

Ironwood Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 3.4 / 5
• Environmental Score: -2.94

Percentage of Shares Shorted

7.58% of the float of Ironwood Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

Ironwood Pharmaceuticals has a short interest ratio ("days to cover") of 5.9.

Change versus previous month

Short interest in Ironwood Pharmaceuticals has recently increased by 1.55%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.0 / 5
• News Sentiment: 0.34

News Sentiment

Ironwood Pharmaceuticals has a news sentiment score of 0.34. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.71 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 8 news articles for Ironwood Pharmaceuticals this week, compared to 4 articles on an average week.

Search Interest

2 people have searched for IRWD on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.

MarketBeat Follows

3 people have added Ironwood Pharmaceuticals to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ironwood Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,316.00 in company stock.

Percentage Held by Insiders

12.90% of the stock of Ironwood Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.

IRWD Stock Analysis - Frequently Asked Questions

How have IRWD shares performed this year?

Ironwood Pharmaceuticals' stock was trading at $11.44 at the start of the year. Since then, IRWD stock has decreased by 61.2% and is now trading at $4.44.
View the best growth stocks for 2024 here.

How were Ironwood Pharmaceuticals' earnings last quarter?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) released its quarterly earnings results on Thursday, May, 9th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by $0.20. The firm's revenue was down 28.0% on a year-over-year basis.

Who are Ironwood Pharmaceuticals' major shareholders?

Top institutional shareholders of Ironwood Pharmaceuticals include Wedge Capital Management L L P NC (0.20%), Inspire Investing LLC (0.06%), Exchange Traded Concepts LLC (0.04%) and Handelsbanken Fonder AB (0.04%). Insiders that own company stock include Thomas A Mccourt, Mark G Currie, Jason Rickard, Michael Shetzline, Sravan Kumar Emany, Minardo John, Andrew Davis, Julie Mchugh, Jon R Duane, Ronald Silver, Catherine Moukheibir and Marla L Kessler.
View institutional ownership trends.

How do I buy shares of Ironwood Pharmaceuticals?

Shares of IRWD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Ironwood Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ironwood Pharmaceuticals investors own include American Water Works (AWK), Humana (HUM), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AUO (AUOTY).

Company Calendar

• Last Earnings: 5/09/2024
• Today: 10/17/2024
• Next Earnings (Estimated): 11/14/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:IRWD
• CUSIP: 46333X10
• CIK: 1446847
• Web: www.ironwoodpharma.com
• Phone: (617) 621-7722
• Fax: 617-494-0480
• Employees: 220
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.17
• High Stock Price Target: $21.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +174.0%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.57
• Research Coverage: 7 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($6.79)
• Trailing P/E Ratio: 111.00
• Forward P/E Ratio: 18.50
• P/E Growth: N/A
• Net Income: $-1,002,240,000.00
• Net Margins: 2.30%
• Pretax Margin: 21.50%
• Return on Equity: -6.37%
• Return on Assets: 4.61%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.92
• Quick Ratio: 3.92

Sales & Book Value

• Annual Sales: $400.57 million
• Price / Sales: 1.74
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($2.21) per share
• Price / Book: -2.01

Miscellaneous

• Outstanding Shares: 156,529,000
• Free Float: 139,133,000
• Market Cap: $694.99 million
• Optionable: Optionable
• Beta: 0.48